These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. The identification of two protective DNA vaccines from a panel of five plasmid constructs encoding Brucella melitensis 16M genes. Commander NJ; Spencer SA; Wren BW; MacMillan AP Vaccine; 2007 Jan; 25(1):43-54. PubMed ID: 17049676 [TBL] [Abstract][Full Text] [Related]
3. Immunological responses and protective efficacy against Brucella melitensis induced by bp26 and omp31 B. melitensis Rev.1 deletion mutants in sheep. Jacques I; Verger JM; Laroucau K; Grayon M; Vizcaino N; Peix A; Cortade F; Carreras F; Guilloteau LA Vaccine; 2007 Jan; 25(5):794-805. PubMed ID: 17070627 [TBL] [Abstract][Full Text] [Related]
4. A recombinant subunit vaccine based on the insertion of 27 amino acids from Omp31 to the N-terminus of BLS induced a similar degree of protection against B. ovis than Rev.1 vaccination. Cassataro J; Pasquevich KA; Estein SM; Laplagne DA; Velikovsky CA; de la Barrera S; Bowden R; Fossati CA; Giambartolomei GH; Goldbaum FA Vaccine; 2007 May; 25(22):4437-46. PubMed ID: 17442465 [TBL] [Abstract][Full Text] [Related]
5. Potential druggable proteins and chimeric vaccine construct prioritization against Brucella melitensis from species core genome data. Aslam M; Shehroz M; Hizbullah ; Shah M; Khan MA; Afridi SG; Khan A Genomics; 2020 Mar; 112(2):1734-1745. PubMed ID: 31678593 [TBL] [Abstract][Full Text] [Related]
7. Rough mutants defective in core and O-polysaccharide synthesis and export induce antibodies reacting in an indirect ELISA with smooth lipopolysaccharide and are less effective than Rev 1 vaccine against Brucella melitensis infection of sheep. Barrio MB; Grilló MJ; Muñoz PM; Jacques I; González D; de Miguel MJ; Marín CM; Barberán M; Letesson JJ; Gorvel JP; Moriyón I; Blasco JM; Zygmunt MS Vaccine; 2009 Mar; 27(11):1741-9. PubMed ID: 19186196 [TBL] [Abstract][Full Text] [Related]
8. Evaluation of Brucella melitensis B115 as rough-phenotype vaccine against B. melitensis and B. ovis infections. Adone R; Francia M; Ciuchini F Vaccine; 2008 Sep; 26(38):4913-7. PubMed ID: 18675869 [TBL] [Abstract][Full Text] [Related]
9. A DNA vaccine coding for the chimera BLSOmp31 induced a better degree of protection against B. ovis and a similar degree of protection against B. melitensis than Rev.1 vaccination. Cassataro J; Pasquevich KA; Estein SM; Laplagne DA; Zwerdling A; de la Barrera S; Bowden R; Fossati CA; Giambartolomei GH; Goldbaum FA Vaccine; 2007 Aug; 25(32):5958-67. PubMed ID: 17600596 [TBL] [Abstract][Full Text] [Related]
10. Nasal immunization with recombinant Brucella melitensis bp26 and trigger factor with cholera toxin reduces B. melitensis colonization. Yang X; Walters N; Robison A; Trunkle T; Pascual DW Vaccine; 2007 Mar; 25(12):2261-8. PubMed ID: 17239499 [TBL] [Abstract][Full Text] [Related]
11. Efficacy of bp26 and bp26/omp31 B. melitensis Rev.1 deletion mutants against Brucella ovis in rams. Grilló MJ; Marín CM; Barberán M; de Miguel MJ; Laroucau K; Jacques I; Blasco JM Vaccine; 2009 Jan; 27(2):187-91. PubMed ID: 19007836 [TBL] [Abstract][Full Text] [Related]
12. Identification of broad cross-protective immunogens using heterogeneous antiserum-based immunoproteomic approach. Li H; Xiong XP; Peng B; Xu CX; Ye MZ; Yang TC; Wang SY; Peng XX J Proteome Res; 2009 Sep; 8(9):4342-9. PubMed ID: 19640004 [TBL] [Abstract][Full Text] [Related]
13. Assessment of genetic stability of Brucella melitensis Rev 1 vaccine strain by multiple-locus variable-number tandem repeat analysis. García-Yoldi D; Le Fleche P; Marín CM; De Miguel MJ; Muñoz PM; Vergnaud G; López-Goñi I Vaccine; 2007 Apr; 25(15):2858-62. PubMed ID: 17050051 [TBL] [Abstract][Full Text] [Related]
14. Immunization with recombinant Brucella species outer membrane protein Omp16 or Omp19 in adjuvant induces specific CD4+ and CD8+ T cells as well as systemic and oral protection against Brucella abortus infection. Pasquevich KA; Estein SM; García Samartino C; Zwerdling A; Coria LM; Barrionuevo P; Fossati CA; Giambartolomei GH; Cassataro J Infect Immun; 2009 Jan; 77(1):436-45. PubMed ID: 18981242 [TBL] [Abstract][Full Text] [Related]
15. Developing antibacterial vaccines in genomics and proteomics era. Kaushik DK; Sehgal D Scand J Immunol; 2008 Jun; 67(6):544-52. PubMed ID: 18397199 [TBL] [Abstract][Full Text] [Related]
16. [The application and research advances of Brucella vaccines]. Ding JB; Mao KR; Cheng JS; Dai ZH; Jiang YW Wei Sheng Wu Xue Bao; 2006 Oct; 46(5):856-9. PubMed ID: 17172046 [TBL] [Abstract][Full Text] [Related]
17. Brucella melitensis B115-based complement fixation test to detect antibodies induced by Brucella rough strains. Adone R; Francia M; Ciuchini F J Appl Microbiol; 2008 Aug; 105(2):567-74. PubMed ID: 18355234 [TBL] [Abstract][Full Text] [Related]
18. Immunopathological responses and kinetics of Brucella melitensis Rev 1 infection after subcutaneous or conjunctival vaccination in rams. Muñoz PM; de Miguel MJ; Grilló MJ; Marín CM; Barberán M; Blasco JM Vaccine; 2008 May; 26(21):2562-9. PubMed ID: 18423950 [TBL] [Abstract][Full Text] [Related]
19. Induction of immune response in mice with a DNA vaccine encoding outer membrane protein (omp31) of Brucella melitensis 16M. Gupta VK; Rout PK; Vihan VS Res Vet Sci; 2007 Jun; 82(3):305-13. PubMed ID: 17014873 [TBL] [Abstract][Full Text] [Related]
20. [Comparative proteomics research on THP-1 cells infected with Brucella]. Gao YH; Ren C; Ying TY; Wang XL Wei Sheng Wu Xue Bao; 2006 Aug; 46(4):629-34. PubMed ID: 17037068 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]